Watch INSM. Know when insiders buy.
One email the day a filing lands. Free.
INSM
INSMED Inc
94.04
−1.63 −1.70%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
32
FLAG · insiders 25, shorts 38
Insiders, 90 days
−$3.1M
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
2 / 15
tracked funds hold it · #2 at Duquesne Family Office
Calls on record
0
nobody we score has called it yet
MKT CAP $20.5BP/E —DIV YIELD —FCF YIELD -3.93%REV TTM $1.1B +185.8%NET INCOME −$875.3MNET DEBT $2M52W 91.88 – 211.41SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $425.5M | +296.1% | 84.2% | −$1.5M | −$13.2M | — | -0.06 | −$88.8M | $6.3M | −$95.1M | Aug 6 |
| Q1 2026 · Mar 31 | $306M | +229.6% | 84.5% | −$153.3M | −$163.6M | — | -0.76 | −$222.7M | $3.5M | −$226.2M | May 7 |
| Q4 2025 · Dec 31derived | $263.8M | +152.6% | 83.2% | −$319.7M | −$328.5M | — | -1.53 | −$247.6M | $16.6M | −$264.2M | Feb 19 |
| Q3 2025 · Sep 30 | $142.3M | +52.4% | 79.4% | −$366M | −$370M | — | -1.75 | −$219.8M | $2.4M | −$222.2M | Oct 30 |
| Q2 2025 · Jun 30 | $107.4M | +18.9% | 73.9% | −$312.9M | −$321.7M | — | -1.70 | −$205.6M | $3.5M | −$209.1M | Aug 6 |
| Q1 2025 · Mar 31 | $92.8M | +22.9% | 77.1% | −$248.1M | −$256.6M | — | -1.42 | −$262.1M | $10.1M | −$272.2M | May 7 |
| Q4 2024 · Dec 31derived | $104.4M | +24.8% | 75.0% | −$230.4M | −$235.5M | — | -1.30 | −$196M | $6.8M | −$202.8M | Feb 19 |
| Q3 2024 · Sep 30 | $93.4M | +18.2% | 77.3% | −$213.4M | −$220.5M | — | -1.27 | −$180.9M | $3.7M | −$184.6M | Oct 30 |
| Q2 2024 · Jun 30 | $90.3M | — | 76.8% | −$288.9M | −$300.6M | — | -1.94 | −$123M | $6.8M | −$129.7M | Aug 7 |
| Q1 2024 · Mar 31 | $75.5M | — | 76.9% | −$145.5M | −$157.1M | — | -1.06 | −$184M | $4.7M | −$188.7M | May 8 |
| Q4 2023 · Dec 31derived | $83.7M | — | 78.0% | −$178.3M | −$186.1M | — | -1.28 | −$130.8M | $2.2M | −$133M | Feb 19 |
| Q3 2023 · Sep 30 | $79.1M | — | 78.9% | −$147.7M | −$158.9M | — | -1.11 | −$136.3M | $2.9M | −$139.2M | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $606.4M | 79.7% | −$1.2B | −$1.3B | -210.5% | -6.42 | −$935M | $32.6M | −$967.6M | — | — |
| FY2024 · to Dec 31 | $363.7M | 76.4% | −$878.3M | −$913.8M | -251.2% | -5.57 | −$683.9M | $21.9M | −$705.8M | — | — |
| FY2023 · to Dec 31 | $305.2M | 78.5% | −$709.6M | −$749.6M | -245.6% | -5.34 | −$536.2M | $13.3M | −$549.5M | — | — |
| FY2022 · to Dec 31 | $245.4M | 77.5% | −$457.3M | −$481.5M | -196.3% | -3.91 | −$400.4M | $9.9M | −$410.3M | — | — |
| FY2021 · to Dec 31 | $188.5M | 76.6% | −$375.1M | −$434.7M | -230.6% | -3.88 | −$363.3M | $7.3M | −$370.6M | — | — |
| FY2020 · to Dec 31 | $164.4M | 75.7% | −$265.2M | −$294.1M | -178.9% | -3.01 | −$219.3M | $6.2M | −$225.6M | — | — |
Every number comes from INSMED Inc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.